Response Biomedical Corp. 

(Public, TSE:RBM)   Watch this stock   
Find more results for RBM

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -155.25% -232.54%
Operating margin -138.01% -221.32%
EBITD margin - -201.26%
Return on average assets -50.70% -73.20%
Return on average equity -95.12% -153.24%
Employees 96 -

Address

100-8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Canada
+1-604-4566010 (Phone)
+1-604-4566066 (Fax)

Website links

Response Biomedical Corp. discussions

  View all discussions »

Description

Response Biomedical Corp. is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical point-of-care (POC) and onsite environmental testing markets. RAMP is the Company's core technology. The Company uses this technology for the commercialization of highly sensitive diagnostic tests in a portable format. This format comprises a fluorescence Reader common to all tests, and single-use, disposable test cartridges that contain an analyte specific, lateral flow immunoassay. Each Cartridge incorporates an internal calibrator. The Company's kits are produced in-house and its Readers are manufactured and supplied under contract. In June 2008, the Company granted Roche Diagnostics (Roche) the rights to market its line of cardiovascular POC tests worldwide. The RAMP cardiovascular product line includes Troponin I, CK-MB, Myoglobin and NT-proBNP.

Officers and directors

Richard J. Bastiani Ph.D.
Chairman of the Board
Age: 66
S. Wayne Kay
Chief Executive Officer, Director
Age: 58
Livleen Kaler
Chief Financial Officer, Vice President - Finance and Administration
Age: 31
Duane A. Morris
Chief Operating Officer
Age: 58
Paul C. Harris Ph.D.
Vice President - Research & Development
Age: 55
Richard K. Bear
Director
Age: 46
Ian A. Webb
Director
Age: 58
Todd R. Patrick
Director
Age: 46
Anthony F. Holler M.D.
Director